Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure

详细信息    查看全文

• 作者：Lesley H. Curtis ; PhD^a ; ^b ; ^{lesley.curtis@duke.edu} ; Xiaojuan Mi ; PhD^a ; Laura G. Qualls ; MS^a ; Bradley G. Hammill ; MS^a ; Stephen C. Hammill ; MD^c ; Paul A. Heidenreich ; MD^d ; Frederick A. Masoudi ; MD ; MSPH^e ; Soko Setoguchi ; MD ; DrPH^a ; ^b ; Adrian F. Hernandez ; MD ; MHS^a ; ^b ; Gregg C. Fonarow ; MD^f
• 刊名：American Heart Journal
• 出版年：2012
• 出版时间：June, 2012
• 年：2012
• 卷：163
• 期：6
• 页码：946-953.e1
• 全文大小：432 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

Despite demonstrated efficacy in randomized trials, aldosterone antagonist therapy is not used in many eligible patients with heart failure. Questions remain about its clinical effectiveness and safety for patients who are underrepresented in randomized trials and those at risk for hyperkalemia.

Methods

The proposed study will evaluate the effectiveness of aldosterone antagonist therapy in eligible Medicare beneficiaries ?5 years old hospitalized for heart failure between 2005 and 2008. Data are from the GWTG-HF registry linked with Medicare inpatient and prescription drug event files. We will use inverse probability-weighted estimators to assess differences in mortality, cardiovascular readmission, and readmission for hyperkalemia between patients who receive or do not receive aldosterone antagonist therapy.

Results

The initial data set included 33,652 patients; 5,463 (16.2 % ) met all inclusion criteria. Compared with patients who did not meet the inclusion criteria, patients in the final cohort were more likely to be younger (77.3 vs 80.3 years) and male (63.8 % vs 41.3 % ) and to have ischemic heart failure (74.2 % vs 59.5 % ) (all P < .001). Mortality rates were 24.7 % at 1 year and 50.7 % at 3 years; cardiovascular readmission rates were 50.1 % at 1 year and 65.2 % at 3 years.

Conclusions

The proposed study will evaluate the clinical effectiveness of aldosterone antagonist therapy in Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction, an underrepresented population in clinical trials. By addressing this evidence gap, the study has the potential to inform clinical decision making and improve patient outcomes.